James R. Wright

54.7k total citations · 3 hit papers
1.0k papers, 39.1k citations indexed

About

James R. Wright is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, James R. Wright has authored 1.0k papers receiving a total of 39.1k indexed citations (citations by other indexed papers that have themselves been cited), including 346 papers in Pulmonary and Respiratory Medicine, 299 papers in Molecular Biology and 192 papers in Oncology. Recurrent topics in James R. Wright's work include Chronic Obstructive Pulmonary Disease (COPD) Research (78 papers), Pancreatic function and diabetes (64 papers) and Lung Cancer Treatments and Mutations (54 papers). James R. Wright is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (78 papers), Pancreatic function and diabetes (64 papers) and Lung Cancer Treatments and Mutations (54 papers). James R. Wright collaborates with scholars based in Canada, United States and United Kingdom. James R. Wright's co-authors include Andrew Churg, Claire Bombardier, Dianne Groll, T. To, Hsin Tai, Changshi Xie, James C. Hogg, Manuel G. Cosío, Peter D. Paré and Ajay Bakhshi and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

James R. Wright

1.0k papers receiving 37.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18

1985 974 citations James R. Wright et al. profile →
The development of a comorbidity index with physical function as the outcome

2005 956 citations James R. Wright et al. profile →
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

2021 170 citations James R. Wright et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
James R. Wright	13.4k	11.2k	8.1k	4.0k	3.9k	1.0k	39.1k
Li Zhang	12.9k 1.0×	5.1k 0.5×	7.6k 0.9×	4.4k 1.1×	6.0k 1.5×	1.9k	39.8k
Steven Piantadosi	5.6k 0.4×	10.1k 0.9×	11.1k 1.4×	4.6k 1.2×	3.2k 0.8×	259	30.5k
Joseph F. Fraumeni	10.2k 0.8×	10.3k 0.9×	14.6k 1.8×	13.0k 3.3×	6.4k 1.7×	474	46.4k
Richard Simon	8.4k 0.6×	6.6k 0.6×	8.7k 1.1×	2.7k 0.7×	5.2k 1.4×	352	35.9k
Kari Hemminki	12.3k 0.9×	4.3k 0.4×	10.1k 1.2×	3.8k 1.0×	9.0k 2.3×	1.0k	35.2k
Elisabeth G.E. de Vries	14.3k 1.1×	7.4k 0.7×	24.1k 3.0×	5.2k 1.3×	6.4k 1.6×	1.0k	47.8k
J. Jack Lee	17.2k 1.3×	11.4k 1.0×	14.9k 1.9×	6.5k 1.6×	7.5k 1.9×	1.1k	50.3k
Richard B. Hayes	9.4k 0.7×	4.9k 0.4×	6.3k 0.8×	3.6k 0.9×	5.5k 1.4×	496	30.6k
David C. Christiani	12.5k 0.9×	13.4k 1.2×	9.3k 1.2×	2.2k 0.6×	6.5k 1.7×	904	44.5k
Stephen M. Schwartz	9.3k 0.7×	3.0k 0.3×	4.7k 0.6×	6.2k 1.6×	3.4k 0.9×	407	30.5k

Countries citing papers authored by James R. Wright

Since Specialization

Citations

This map shows the geographic impact of James R. Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Wright more than expected).

Fields of papers citing papers by James R. Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Wright. The network helps show where James R. Wright may publish in the future.

Co-authorship network of co-authors of James R. Wright

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Wright. A scholar is included among the top collaborators of James R. Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Wright. James R. Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leyton‐Brown, Kevin, et al.. (2024). How to Evaluate Behavioral Models. Proceedings of the AAAI Conference on Artificial Intelligence. 38(9). 9636–9644. 1 indexed citations

Beckett, Emma, Flávia Fayet‐Moore, Tim Cassettari, et al.. (2024). The balance of evidence on 100% juice & health: A systematic umbrella review of meta-analyses. Proceedings of The Nutrition Society. 83(OCE1). 1 indexed citations

Heumann, Thatcher, Mark Yarchoan, Jiayun Lu, et al.. (2024). A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). 4017–4017. 3 indexed citations

Churg, Andrew, Henry D. Tazelaar, Radoslav Matěj, et al.. (2023). Pathologic Criteria for the Diagnosis of Usual Interstitial Pneumonia vs Fibrotic Hypersensitivity Pneumonitis in Transbronchial Cryobiopsies. Modern Pathology. 36(9). 100221–100221. 4 indexed citations

Longo, Christopher J., Margaret I. Fitch, Jonathan M. Loree, et al.. (2021). Patient and family financial burden associated with cancer treatment in Canada: a national study. Supportive Care in Cancer. 29(6). 3377–3386. 56 indexed citations

Srivastava, Apurva K., Melinda G. Hollingshead, Jeevan Prasaad Govindharajulu, et al.. (2018). Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics. 17(3). 698–709. 7 indexed citations

Ivaturi, Vijay, Jogarao Gobburu, Jacqueline M. Greer, et al.. (2017). Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. Clinical Cancer Research. 23(14). 3592–3600. 9 indexed citations

Arsenault, Julie, Sameer Parpia, Harold Reiter, et al.. (2015). Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 93(3). S59–S59. 5 indexed citations

Appleman, Leonard J., Sanjeeve Balasubramaniam, Robert A. Parise, et al.. (2014). A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. Clinical Cancer Research. 21(4). 721–729. 5 indexed citations

10.

Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883. 26 indexed citations

11.

Davies, Michael A., Patricia S. Fox, Nicholas E. Papadopoulos, et al.. (2012). Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research. 18(4). 1120–1128. 39 indexed citations

12.

Kelly, Ronan J., Arun Rajan, Jeremy Force, et al.. (2011). Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research. 17(5). 1190–1199. 58 indexed citations

13.

Argiris, Athanassios, Austin G. Duffy, Shivaani Kummar, et al.. (2011). Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer. Clinical Cancer Research. 17(17). 5755–5764. 44 indexed citations

14.

Wright, James R.. (2010). Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy. Clinical Cancer Research. 16(16). 4094–4104. 83 indexed citations

15.

Huesca, Mario, Lisa Lock, Aye Aye Khine, et al.. (2009). A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis. Molecular Cancer Therapeutics. 8(9). 2586–2596. 26 indexed citations

16.

Kloos, Richard T., Matthew D. Ringel, Michael V. Knopp, et al.. (2009). Phase II Trial of Sorafenib in Metastatic Thyroid Cancer. Journal of Clinical Oncology. 27(10). 1675–1684. 430 indexed citations

17.

Dahut, William L., Charity D. Scripture, Edwin M. Posadas, et al.. (2008). A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research. 14(1). 209–214. 142 indexed citations

18.

Sparano, Joseph A., Stacy L. Moulder, Aslamuzzaman Kazi, et al.. (2006). Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide. Journal of Clinical Oncology. 24(19). 3013–3018. 54 indexed citations

19.

Churg, Andrew, et al.. (2004). Tumor Necrosis Factor-α Drives 70% of Cigarette Smoke–induced Emphysema in the Mouse. American Journal of Respiratory and Critical Care Medicine. 170(5). 492–498. 285 indexed citations

20.

Schnitzer, M. & James R. Wright. (1960). Nitric Acid Oxidation of the Organic Matter of a Podzol. Soil Science Society of America Journal. 24(4). 273–276. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact